七氟丁酸乙烯酯 | 356-28-5

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机卤素化合物 - 卤代烷
• 中文名称: 七氟丁酸乙烯酯
• 英文名称: heptafluoro-butyric acid vinyl ester
• 英文别名: Heptafluor-buttersaeure-vinylester；heptafluoro-butanoic acid, ethenyl ester；Vinyl heptafluorobutyrate；Perfluorbuttersaeure-vinylester；Vinylheptafluorbutyrat；ethenyl 2,2,3,3,4,4,4-heptafluorobutanoate
• CAS: 356-28-5
• 化学式: C₆H₃F₇O₂
• mdl: MFCD09259000
• 分子量: 240.077
• InChiKey: CJABYGHRZGXUKQ-UHFFFAOYSA-N

物化性质

• 沸点：
  79°C (rough estimate)
• 密度：
  1.4180

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  9

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R11
• 危险品运输编号：
  UN 1993
• 海关编码：
  2915900090
• 安全说明：
  S16,S29,S33

反应信息

• 作为产物：
  描述：

  七氟丁酸 在 mercury(II) oxide 作用下， 生成 七氟丁酸乙烯酯 、 1,1-bis-heptafluorobutyryloxy-ethane
  参考文献：
  名称：

  全氟酸乙烯基酯

  摘要：

  已经通过酸与乙炔的汞催化反应制备了一系列七种全氟酸乙烯基酯。给出了单体的某些物理特性。除了辛酸乙烯酯和癸酸乙烯酯形成蜡状薄膜外，均聚物可产生透明、柔韧的薄膜。全氟丁酸乙烯酯与乙酸乙烯酯和甲基丙烯酸甲酯的共聚很容易进行，但与苯乙烯、马来酸酐和丙烯腈的共聚则较难进行。

  DOI：

  10.1002/pol.1955.120188911

文献信息

• Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
  申请人：Gregory Jefferson J.

  公开号：US20100160368A1

  公开（公告）日：2010-06-24

  Pharmaceutical Formulations and Methods for the Topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namely, viral infections, such as Type I or Type II Herpes simplex infections and genital and perianal warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis to achieve an antiviral effect, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration (“FDA”).

  制药配方和方法用于局部和/或经皮递送依米奎莫德，包括面霜、软膏和压敏粘合剂组合物，用于治疗皮肤疾病，即病毒感染，如I型或II型单纯疱疹感染和生殖器及肛门疣、日光性角化症和浅表性基底细胞癌，并诱导干扰素生物合成以实现抗病毒效果，比目前由美国食品药品监督管理局（FDA）批准的依米奎莫德疗程时间更短。
• METHODS OF TREATING DERMATOLOGICAL DISORDERS AND INDUCING INTERFERON BIOSYNTHESIS WITH SHORTER DURATIONS OF IMIQUIMOD THERAPY
  申请人：Gregory Jefferson J.

  公开号：US20090018155A1

  公开（公告）日：2009-01-15

  Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namely, viral infections, such as Type I or Type II Herpes simplex infections and genital warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration (“FDA”).

  制药配方和方法，用于局部和/或经皮递送咪喹莫德（imiquimod），包括乳膏、软膏和压敏粘合剂组合物，用于治疗皮肤疾病，即病毒感染，如I型或II型单纯疱疹感染和生殖器疣，光化性角化症和表浅性基底细胞癌，并诱导干扰素生物合成，比目前由美国食品和药物管理局（“FDA”）批准的咪喹莫德治疗时间更短。
• METHODS AND PACKAGES TO ENHANCE SAFETY WHEN USING IMIQUIMOD TO TREAT CHILDREN DIAGNOSED WITH SKIN DISORDERS
  申请人：Slade Herbert B.

  公开号：US20080280943A1

  公开（公告）日：2008-11-13

  Pharmaceutical packages and methods for enhancing the safety of imiquimod when used to treat children affected by skin disorders are disclosed. More particularly, the safety profile of imiquimod use is enhanced by providing information to the children, guardians of the children, including parents and health care professionals, that systemic absorption of imiquimod and other effects may be observed when imiquimod therapy is used to treat children of between about 2 and about 12 years of age. Examples of systemic absorption include a serum imiquimod concentrations of less than about 2 ng/mL, a decrease in median white blood cell count by about 1.4*10 9 /L or a decrease in median absolute neutrophil count by about 1.42*10 9 /L. Topical and/or transdermal delivery of imiquimod, including creams, ointments, gels, lotions, salves and pressure-sensitive adhesive compositions to treat dermatological disorders in children, namely, molluscum contagiosum, viral infections, such as Type I or Type II Herpes simplex infections and condyloma acuminata, genital warts and perianal warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis, are disclosed.

  本发明涉及药物包装和方法，用于增强使用咪喹莫德治疗患有皮肤疾病的儿童的安全性。特别地，通过向儿童、儿童监护人（包括父母和医护人员）提供信息，即在使用咪喹莫德治疗2至12岁儿童时可能观察到咪喹莫德的系统吸收和其他影响，增强了咪喹莫德使用的安全性。系统吸收的示例包括血清咪喹莫德浓度低于约2ng/mL、中位白细胞计数降低约1.4*109/L或中位绝对中性粒细胞计数降低约1.42*109/L。本发明还涉及用于治疗儿童皮肤病的咪喹莫德的局部和/或经皮递送，包括乳膏、软膏、凝胶、洗剂、膏药和压敏粘合剂组合物，用于治疗软疣、病毒感染（如I型或II型单纯疱疹感染和尖锐湿疣）、光化性角化症和浅表性基底细胞癌，并诱导干扰素生物合成。
• Molecular Healing of Polymeric Materials, Coatings, Plastics, Elastomers, Composites, Laminates, Adhesives, and Sealants by Active Enzymes
  申请人：McDaniel C. Steven

  公开号：US20100210745A1

  公开（公告）日：2010-08-19

  Disclosed herein are polymeric materials such as a coating, a plastic, a laminate, a composite, an elastomer, an adhesive, or a sealant; a surface treatment such as a textile finish or a wax; a filler for such a polymeric material or a surface treatment that includes an enzyme such as an esterase (e.g., a lipolytic enzyme, a sulfuric ester hydrolase, an organophosphorus compound degradation enzyme), an enzyme (e.g., a lysozyme, a lytic transglycosylase) that degrades a cell wall and/or a cell membrane component, a biocidal or biostatic peotide, and/or a peptidase. Also disclosed herein are methods of altering a material's property such as service life, flexability, or rigidity, by incorporation of an enzyme into a material capable of being chemically crosslinked by the activity of a lipolytic enzyme, a hydrolase, and/or a urease.

  本文公开了一些聚合材料，如涂层、塑料、层压板、复合材料、弹性体、粘合剂或密封剂；一种表面处理，如纺织品涂层或蜡；一种填料，用于这样的聚合材料或表面处理，其中包括一种酶，如酯酶（例如，脂肪水解酶，硫酸酯水解酶，有机磷化合物降解酶），降解细胞壁和/或细胞膜成分的酶（例如，溶菌酶，裂解转糖基酶），生物杀菌或生物静态肽，以及/或肽酶。本文还公开了通过将酶纳入可通过脂肪水解酶、水解酶和/或脲酶的活性交联材料中来改变材料性能，如使用寿命、柔韧性或刚度的方法。
• LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS
  申请人：Nordsiek Michael T.

  公开号：US20110207766A1

  公开（公告）日：2011-08-25

  Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.

  本文公开了用于治疗生殖器/会阴疣的局部或经皮递送1-异丁基-1H-咪唑[4,5-c]-喹啉-4-胺或1-(2-甲基丙基)-1H-咪唑[4,5 c]喹啉-4-胺（即Imiquimod）的制剂和方法，其治疗时间比商业可获得的Aldara® 5% Imiquimod Cream目前所规定的时间更短，已获得美国食品药品监督管理局（FDA）批准。更具体地，本文还公开了较低剂量的Imiquimod制剂，以递送有效剂量的Imiquimod治疗生殖器/会阴疣，并具有可接受的安全性和更短、更方便的用药方案，比美国FDA批准的Aldara® 5% Imiquimod Cream治疗生殖器/会阴疣的用药方案更短。

表征谱图